- Which hormone is most likely to exhibit a markedly reduced peak secretion at her current 7 AM compared with her usual home schedule?
Answer: Cortisol released from the zona fasciculata under ACTH control
When you encounter questions about jet lag and hormone disruption, focus on circadian rhythms and how they're controlled by light-dark cycles and the suprachiasmatic nucleus.
Jet lag occurs when your internal biological clock becomes misaligned with the local time zone. After traveling east across eight time zones, this flight attendant's circadian rhythms are still synchronized to her home time zone, meaning her body thinks it's midnight when the local clock shows 7 AM.
Cortisol follows a strong circadian pattern with peak secretion normally occurring in early morning (around 6-8 AM) to help with awakening and provide energy for the day. Since her internal clock is 8 hours behind, her cortisol peak would occur at what feels like her usual morning time (local 3 PM), not at the current local 7 AM. This makes option A correct.
Let's examine why the other options are wrong: Option B (melatonin) would actually show increased secretion at local 7 AM since her body perceives this as nighttime - the opposite of "markedly reduced." Option C (parathyroid hormone) is regulated primarily by serum calcium levels, not circadian rhythms, so jet lag wouldn't significantly affect its secretion pattern. Option D (prolactin) does have some circadian variation but is much less pronounced than cortisol's dramatic morning surge.
Remember that cortisol has the most robust circadian rhythm of major hormones, with a sharp morning peak that's easily disrupted by jet lag. This makes it a favorite topic for USMLE questions about circadian disruption.
- Octreotide exerts its therapeutic effect by acting on the pituitary somatotrophs to directly cause which of the following?
Answer: Inhibition of GH release
Somatostatin is a hormone produced by the hypothalamus that acts as the primary inhibitor of growth hormone (GH) secretion from the anterior pituitary. Octreotide, a somatostatin analog, mimics this action. It binds to somatostatin receptors on the somatotroph cells of the pituitary, which inhibits the release of stored GH into the circulation. This leads to lower circulating GH levels and, consequently, reduced IGF-1 production by the liver.
- Measurement of which of the following substances provides the most accurate reflection of pancreatic beta-cell insulin secretion?
Answer: C-peptide
Insulin is synthesized as a larger precursor molecule, proinsulin, which is cleaved in beta-cell secretory granules into active insulin and C-peptide. Both are then co-secreted in equimolar amounts. Unlike insulin, C-peptide is not significantly cleared by the liver (no first-pass metabolism) and has a longer half-life. Therefore, measuring C-peptide levels is a more reliable indicator of endogenous insulin secretion than measuring insulin itself.
- The undetectable ACTH level in this patient is a direct result of which of the following physiologic mechanisms?
Answer: Negative feedback by cortisol on the pituitary and hypothalamus
This patient has Cushing syndrome due to a cortisol-producing adrenal adenoma. The autonomously secreted cortisol exerts strong negative feedback on the hypothalamus (suppressing CRH release) and the anterior pituitary (suppressing ACTH release). This leads to an undetectable plasma ACTH level, which is a key feature distinguishing primary adrenal causes of Cushing syndrome from pituitary or ectopic ACTH-producing causes.
- Which of the following mechanisms best explains the initial rise and subsequent fall in this patient's serum testosterone concentration during continuous leuprolide therapy?
Answer: Desensitization and down-regulation of gonadotroph GnRH receptors after sustained agonist exposure
When you encounter questions about GnRH agonists like leuprolide, focus on the paradoxical biphasic response these drugs create in the hypothalamic-pituitary-gonadal axis.
Leuprolide is a GnRH receptor agonist that initially stimulates gonadotroph cells in the anterior pituitary, causing an acute release of LH and FSH. This surge drives increased testosterone production from Leydig cells, explaining the initial rise above baseline in the first 3 days. However, continuous exposure to this potent agonist leads to desensitization and down-regulation of GnRH receptors on gonadotroph cells. Without functional receptors, LH and FSH secretion plummets, causing testosterone levels to fall dramatically below baseline by day 10. This mechanism makes leuprolide effective for androgen-dependent prostate cancer treatment.
Answer choice A correctly describes this receptor desensitization and down-regulation process. Choice B is incorrect because 17-α-hydroxylase saturation doesn't explain the biphasic pattern - enzyme saturation would cause a plateau, not this specific rise-then-fall pattern. Choice C involves 5-α-reductase inhibition (like finasteride), which would decrease DHT but actually increase serum testosterone levels, opposite to what's observed. Choice D suggests enhanced hepatic clearance, but this wouldn't create the initial testosterone surge seen in the first three days.
Remember that GnRH agonists create a "flare" effect before suppression. This concept appears frequently on Step 1, so always think "initial stimulation, then receptor down-regulation" when you see continuous GnRH agonist therapy questions.
- Blockade of which hypothalamic-pituitary interaction most directly accounts for her hyperprolactinemia?
Answer: Tonic inhibition of lactotrophs by dopamine released from tuberoinfundibular neurons
When you encounter antipsychotic-induced hyperprolactinemia, focus on the normal regulatory mechanism that's being disrupted. Under physiological conditions, prolactin secretion from anterior pituitary lactotrophs is under tonic inhibitory control by dopamine released from tuberoinfundibular neurons in the hypothalamus. This means dopamine constantly suppresses prolactin release.
Risperidone is an antipsychotic that blocks dopamine D2 receptors throughout the brain, including those on lactotrophs. When these receptors are blocked, the normal inhibitory signal is removed, leading to unopposed prolactin secretion. This explains both the galactorrhea (milk production) and menstrual irregularities (prolactin suppresses GnRH release).
Choice A correctly identifies this mechanism - the blockade of tonic dopaminergic inhibition from tuberoinfundibular neurons is directly responsible for the hyperprolactinemia.
Choice B is incorrect because while TRH can stimulate prolactin release, this pathway is not the primary mechanism affected by risperidone, nor is cold exposure relevant here. Choice C contains a fabricated mechanism - prolactin doesn't provide positive feedback to mammillary body neurons in any clinically relevant pathway. Choice D is wrong because somatostatin primarily inhibits growth hormone and TSH release, not prolactin, and hypothalamic D cells aren't the relevant source.
Remember that antipsychotic-induced endocrine side effects almost always trace back to dopamine receptor blockade. Dopamine's inhibitory role in prolactin regulation makes hyperprolactinemia one of the most predictable side effects of dopamine-blocking medications.
- The enzyme that catalyzes the final step of epinephrine synthesis is phenylethanolamine-N-methyltransferase (PNMT). The expression and activity of this enzyme are highly dependent on induction by which of the following hormones?
Answer: Cortisol
The adrenal medulla is located anatomically adjacent to the adrenal cortex. The enzyme PNMT, which converts norepinephrine to epinephrine, is found primarily in the adrenal medulla. Its synthesis is induced by the high local concentrations of cortisol draining from the adrenal cortex into the medullary sinusoids. This anatomical relationship explains why the adrenal medulla is the primary site of epinephrine production.
- The intracellular signaling pathway initiated by glucagon binding to its receptor involves a Gs protein-mediated increase in the concentration of which second messenger?
Answer: Cyclic adenosine monophosphate (cAMP)
Glucagon binds to a G-protein coupled receptor (GPCR) on hepatocytes. This activates the associated Gs protein, which in turn activates adenylyl cyclase. Adenylyl cyclase catalyzes the conversion of ATP to cyclic AMP (cAMP). cAMP then activates protein kinase A (PKA), which phosphorylates enzymes involved in glycogenolysis and gluconeogenesis, ultimately leading to an increase in blood glucose.
- Administration of hydrocortisone decreases this patient's adrenal androgen overproduction primarily through which of the following actions?
Answer: Negative feedback inhibition of corticotropin-releasing hormone and ACTH secretion
When you encounter congenital adrenal hyperplasia questions, focus on the underlying enzyme deficiency and how hormone replacement restores normal feedback loops.
In 21-hydroxylase deficiency, the enzyme block prevents conversion of 17-hydroxyprogesterone to cortisol. With inadequate cortisol production, the hypothalamic-pituitary-adrenal axis loses its normal negative feedback inhibition. This causes persistently elevated CRH and ACTH secretion, which overstimulates the adrenal glands. The excess ACTH drives precursor steroids down alternative pathways, leading to androgen overproduction and salt-wasting from inadequate mineralocorticoid synthesis.
Hydrocortisone replacement works by restoring the missing cortisol, which then provides negative feedback inhibition at both the hypothalamus (suppressing CRH) and anterior pituitary (suppressing ACTH). With normalized ACTH levels, the pathological overstimulation of androgen-producing pathways resolves. This makes choice (A) correct.
Choice (B) is incorrect because hydrocortisone doesn't directly inhibit 17,20-lyase enzyme activity—it works through the feedback mechanism. Choice (C) is wrong because hydrocortisone doesn't antagonize androgen receptors; it's a glucocorticoid that reduces androgen production itself. Choice (D) is incorrect because LH receptors aren't relevant here—adrenal androgen production is ACTH-dependent, not LH-dependent, and the zona reticularis doesn't have significant LH receptors.
Remember: In CAH questions, hormone replacement therapy works by restoring normal feedback inhibition, not by directly blocking enzymes or receptors downstream.
- Angiotensin II stimulates aldosterone synthesis in zona glomerulosa cells via which intracellular signaling pathway?
Answer: Gq-mediated activation of phospholipase C with generation of IP₃ and diacylglycerol
When you encounter questions about hormone signaling pathways, focus on matching the specific hormone to its characteristic receptor type and downstream cascade. Angiotensin II is a peptide hormone that cannot cross cell membranes, so it must work through surface receptors.
Angiotensin II binds to AT₁ receptors on zona glomerulosa cells in the adrenal cortex. These are G-protein coupled receptors (GPCRs) specifically linked to Gq proteins. When activated, Gq stimulates phospholipase C, which cleaves PIP₂ into two crucial second messengers: IP₃ and diacylglycerol (DAG). IP₃ triggers calcium release from intracellular stores, while DAG activates protein kinase C. This calcium-dependent signaling ultimately leads to aldosterone synthesis and secretion.
Choice A correctly describes this Gq-phospholipase C pathway. Choice B describes the Gs-cAMP pathway, which is used by hormones like ACTH, TSH, and glucagon, but not angiotensin II. Choice C refers to cytokine signaling through receptor tyrosine kinases and JAK-STAT pathways, which are characteristic of growth factors and interferons, not angiotensin II. Choice D mentions cGMP-gated channels, which are involved in signaling pathways like those triggered by nitric oxide or natriuretic peptides, not angiotensin II.
Remember that the renin-angiotensin-aldosterone system uses the Gq pathway for both vasoconstriction (smooth muscle) and aldosterone synthesis (adrenal cortex). This consistent mechanism across target tissues makes it easier to remember than trying to memorize each pathway separately.
- The synthesis of thyroid hormones is impaired in this patient due to the insufficient availability of a substrate required for which of the following steps?
Answer: Coupling of monoiodotyrosine and diiodotyrosine
This patient has hypothyroidism and goiter due to dietary iodine deficiency. Iodine is essential for the synthesis of thyroid hormones. It is oxidized and attached to tyrosine residues on thyroglobulin (organification) to form monoiodotyrosine (MIT) and diiodotyrosine (DIT). The subsequent coupling of these molecules (e.g., DIT + DIT -> T4) to form active hormone is therefore critically dependent on adequate iodine supply. The other steps listed are not directly dependent on iodine.
- Binding of insulin to its target-cell receptor initiates which immediate intracellular event?
Answer: Autophosphorylation of intrinsic tyrosine kinase domains on the β-subunits of the receptor
When you encounter questions about insulin signaling, focus on the fact that insulin uses a receptor tyrosine kinase (RTK) mechanism, which is fundamentally different from G-protein coupled receptors or ion channels.
The insulin receptor is a tetrameric protein consisting of two α-subunits (extracellular, insulin-binding) and two β-subunits (transmembrane, containing intracellular tyrosine kinase domains). When insulin binds to the α-subunits, it causes a conformational change that brings the β-subunits closer together. This proximity allows the tyrosine kinase domains on each β-subunit to phosphorylate specific tyrosine residues on the adjacent β-subunit—a process called autophosphorylation. This autophosphorylation is the immediate molecular event that initiates the entire insulin signaling cascade, leading to downstream effects like glucose uptake and metabolic changes.
Option B describes Gq-protein signaling typical of receptors like those for angiotensin II or α1-adrenergic receptors, not insulin. Option C describes ligand-gated ion channels like GABA or glycine receptors, which cause rapid electrical changes rather than metabolic signaling. Option D describes guanylate cyclase signaling seen with atrial natriuretic peptide or nitric oxide pathways, not insulin.
The correct answer is A because autophosphorylation of the β-subunit tyrosine kinase domains is the immediate intracellular consequence of insulin binding.
Study tip: Remember that insulin, IGF-1, EGF, and PDGF all use receptor tyrosine kinases. When you see these hormones/growth factors on the USMLE, think "autophosphorylation" as the first step in their signaling cascades.
- The deficient enzyme in this condition is responsible for converting precursors into aldosterone and cortisol. All adrenal steroid hormones are ultimately synthesized from which common precursor molecule?
Answer: Cholesterol
All steroid hormones, including glucocorticoids (cortisol), mineralocorticoids (aldosterone), and adrenal androgens, are synthesized from cholesterol. In 21-hydroxylase deficiency, the pathways leading to cortisol and aldosterone are blocked. This shunts the common cholesterol-derived precursors towards the androgen synthesis pathway, leading to excess androgen production and virilization. The lack of cortisol and aldosterone causes the other clinical findings.
- The long-term therapeutic effect of this continuous GnRH agonist is due to which of the following changes in the pituitary gonadotrophs?
Answer: Downregulation of GnRH receptors
The normal physiologic secretion of GnRH from the hypothalamus is pulsatile. This pulsatility is required to stimulate the pituitary gonadotrophs to release LH and FSH. Continuous, non-pulsatile administration of a GnRH agonist initially stimulates LH/FSH release but then leads to the downregulation and desensitization of GnRH receptors on the gonadotrophs. This ultimately suppresses LH and FSH secretion, leading to a state of medical hypogonadism.
- The binding of GH to its receptor on hepatocytes normally triggers an intracellular signaling cascade that relies on the activation of which pathway?
Answer: JAK-STAT pathway
The growth hormone receptor is a member of the cytokine receptor superfamily. Unlike tyrosine kinase receptors, it lacks intrinsic kinase activity. Upon GH binding, the receptor dimerizes and recruits Janus kinases (JAKs), which are intracellular tyrosine kinases. The activated JAKs phosphorylate each other and the receptor itself, creating docking sites for Signal Transducer and Activator of Transcription (STAT) proteins. STATs are then phosphorylated, dimerize, and translocate to the nucleus to regulate gene transcription, including the gene for IGF-1.
- Thyroid-stimulating hormone binds its receptor on thyroid follicular cells to increase iodide uptake and thyroid hormone synthesis. Which second-messenger system is primarily used by the TSH receptor to mediate these actions?
Answer: Activation of adenylate cyclase with generation of intracellular cAMP
When you encounter questions about hormone signaling pathways, focus on matching the hormone type to its characteristic second-messenger system. TSH is a glycoprotein hormone that works through G-protein coupled receptors (GPCRs).
The TSH receptor is a classic Gs-coupled receptor. When TSH binds, it activates the Gs protein, which stimulates adenylate cyclase to convert ATP into cyclic adenosine monophosphate (cAMP). This elevated cAMP then activates protein kinase A (PKA), which phosphorylates key enzymes involved in iodide uptake and thyroid hormone synthesis. The cAMP pathway is essential for TSH's ability to increase both the sodium-iodide symporter activity and thyroglobulin production.
Option A is correct because TSH specifically uses the adenylate cyclase/cAMP system to mediate its effects on thyroid follicular cells.
Option B describes the phospholipase C pathway that generates IP₃ and DAG. This pathway is used by hormones like TRH (thyrotropin-releasing hormone) and some other GPCR ligands, but not TSH itself.
Option C involves receptor tyrosine kinase signaling, which is characteristic of growth factors like insulin and EGF, not glycoprotein hormones like TSH.
Option D describes ligand-gated ion channels, which are used by neurotransmitters like acetylcholine at the neuromuscular junction, not by peptide hormones acting on metabolic targets.
Remember this pattern: anterior pituitary hormones (TSH, LH, FSH, ACTH) typically work through Gs-coupled receptors and the cAMP pathway. This is a high-yield association for endocrinology questions on Step 1.
- Sustained high estradiol concentrations at this point in the cycle exert which effect on the hypothalamic-pituitary axis to trigger ovulation?
Answer: Positive feedback on pituitary gonadotrophs leading to an abrupt surge in luteinizing hormone secretion
Understanding the menstrual cycle requires grasping how estradiol's effects on the hypothalamic-pituitary axis change depending on its concentration and timing. Day 13 represents the late follicular phase, when the dominant follicle produces rapidly rising estradiol levels.
At sustained high concentrations (above approximately 200 pg/mL for 36+ hours), estradiol switches from negative to positive feedback on the hypothalamic-pituitary axis. This positive feedback dramatically increases GnRH pulse frequency and amplitude, which in turn stimulates pituitary gonadotrophs to release a massive surge of LH (and to a lesser extent, FSH). This LH surge is what triggers ovulation approximately 36 hours later. Answer A correctly describes this mechanism.
Answer B describes estradiol's typical negative feedback effect, which occurs at lower concentrations throughout most of the follicular phase - but not during the pre-ovulatory surge when concentrations are sustained at high levels.
Answer C misrepresents the mechanism entirely. High estradiol doesn't inhibit FSH receptors on the follicle; rather, the dominant follicle becomes increasingly sensitive to gonadotropins and continues producing more estradiol.
Answer D incorrectly suggests prolactin involvement. While prolactin can suppress gonadotropins when chronically elevated (as in hyperprolactinemia), it's not part of the normal ovulatory mechanism triggered by high estradiol.
Remember this key concept: estradiol exhibits biphasic feedback - negative feedback at moderate levels, but positive feedback at sustained high levels. This switch from negative to positive feedback is what makes ovulation possible in the normal menstrual cycle.
- Assuming a normal circadian rhythm, a blood sample drawn at which of the following times would most likely show the highest plasma cortisol concentration?
Answer: 8:00 AM
Cortisol secretion follows a distinct diurnal (circadian) rhythm, regulated by the hypothalamic suprachiasmatic nucleus. Levels are lowest in the late evening, around midnight, and begin to rise in the early morning hours. The peak cortisol level typically occurs shortly after awakening, between 6:00 AM and 8:00 AM. This morning surge helps prepare the body for the stresses of the day.
- The development of diabetes mellitus in this patient is largely due to the inhibitory effect of somatostatin on the secretion of which of the following hormones?
Answer: Insulin and glucagon
Somatostatin is a potent inhibitory hormone. In the pancreas, it is secreted by delta cells and acts in a paracrine fashion to inhibit the secretion of both insulin (from beta cells) and glucagon (from alpha cells). In a somatostatinoma, the massive oversecretion of somatostatin leads to profound suppression of insulin release, which impairs glucose uptake and utilization, resulting in hyperglycemia and diabetes mellitus. It also inhibits glucagon, but the effect of insulin inhibition predominates.
- Which of the following changes is expected after initiating octreotide therapy?
Answer: Decreased secretion of growth hormone from anterior pituitary somatotrophs
When you encounter questions about hormone therapies, focus on understanding the normal physiological pathways and how medications either mimic or block natural hormones.
Octreotide is a synthetic somatostatin analog that mimics the action of natural somatostatin. In healthy individuals, somatostatin is released from the hypothalamus and acts as a brake on growth hormone (GH) secretion from anterior pituitary somatotrophs. In acromegaly, there's excessive GH production, often from a pituitary adenoma. Octreotide binds to somatostatin receptors on these somatotrophs and directly inhibits GH release, making choice A correct.
Choice B is incorrect because IGF-1 production by the liver is stimulated by growth hormone. Since octreotide decreases GH secretion, IGF-1 levels would actually decrease, not increase. Choice C represents a common misconception about feedback loops. While octreotide does reduce GH levels, it doesn't work through the hypothalamus—it acts directly on the pituitary. The hypothalamic response would actually be to increase GHRH production due to negative feedback, but this isn't the primary therapeutic mechanism. Choice D confuses octreotide's effects with those of dopamine agonists. Octreotide primarily targets somatotrophs, and while it may have some effect on prolactin, this isn't its main action or the expected therapeutic change in acromegaly treatment.
Remember that somatostatin analogs work by directly mimicking the body's natural "off switch" for growth hormone. This direct inhibition is why they're effective in treating the excess GH production characteristic of acromegaly.
